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the Ver.tak P, the PCD offers low energy cardioversion (LEC) as well 
as antitachycardia pacing lities (ATP). In 13f39 pts and 9116 pts 
a sustained monomorphic cular tachycardia (mVT) (CL 270+34 
ms and 29OM5 ms. respectively) could be induced. C (5 4 joules) 
reproducibly terminated mVT in 6/l 3 pts but caused acceleration into 
VF in 7/13 pts. In 5 of these 7 pts the second shock (S2 twice DFT) 
terminated VF but S2 to S5 failed to terminate VF in the other 2 pts. 
When VF was induced in the 6 pts with successful LEC VT termina- 
tion, VF was terminated in 5 but not in the 6th pt. LEC was always 
associated with moderate to severe pain. In the 9/16 PCD pts termina- 
tion of mVT was either attempted by burst (fixed # of pulses with 
decreasing CL between attempts) or ramp pacmg (increasing # of 
pulses with decreasing CL within attempts). In 719 pts mVT was 
reproducibly terminated by either pacing mode, failed VT termination 
in 1 pt and caused VT acceleration in 
cess rminated due to a different 
tion : Ventak P mediated LEC terminates mVT in 46% 
but accelerates VT to VF in 54% and prevents conversion of primary 
VF in 23%. In contrast, PCD mediated ATP terminated mVT in 78%. 
accelerated in 11% and was unsuccessful in 11%. Since EC was 
always painful for the pts, ATP and not LEC should be the treatment 
of choice for mVT. In addition, different algorithms for VT and VF 
detection make the PCD superior to the Vent& P. 
occasions. 
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In 84 mongrel dogs the ac 
intravenous propafenone ( 
and maintenance) on 
ventricular defibrillation energy 
requirements (DER) were investigated 
using an intravenous sp 
~pi~rdiai h electrode 
was attem 10 seconds 
of ventricular fibrillation by testing 
randomly muldple stored energy levels. 
The percenl successful defibrillation was 
plolled against the stored energy and the 
raw data fit by logistic regression. The Pie FOSl 
DER for 50% (E50) and 80% (EN) 
defibrillation success increased post-propafenone treatment in every dog 
(Figure: continuous lines) and in the group (n=lO) by a mean of 75% 
@SO: 8.4024J to 14.725.9J. ~~0.05) and 59% (ESO: ll.lt3.5J 10 19.6~6.73, 
pd.O5), respectively. Plasma propafenone levels ranged born 
1495*592ng/ml at the beginning to 1297&39ng/ml at the end of Ihe 
defibrillation trials and were within reported therapeutic range. ‘fkvo dogs 
ed no incr 
could no 
none increases the internal vemricular 
in contrast 10 previous results obtained 
supports the hypothesis ahat so-called class Ic agent5 
elevabz the DER. may have important clinical implications in patients 
with an implantable defibrillator receiving concomitant drug therapy with 
propafenone and in palienls receiving inlravenous propafenone. 
